Colowick Alan
Colowick Alan's purchase track record
Colowick Alan has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/1/2025 | ALMS | $130K | -58.3% | -44.9% | +18.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Competitors Tempus and Natera draw market attention. Recent news highlights increased activity by Personalis competitors. Tempus AI is expanding its cancer vaccine infrastructure with Moderna and Merck, while Natera faces rising competitive threats. These developments underscore the crowded nature of the precision medicine sector, providing context for Personalis's current trading position near its support levels.
Transaction History
| ALMS | ▲ Buy | Open Market | 2,300 | $17K | 4/2/2025 | View on chart |
| ALMS | ▲ Buy | Open Market | 16,104 | $112K | 4/1/2025 | View on chart |
| PSNL | ▲ Buy | Grant | 10,770 | $0 | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Alumis reports positive Phase 3 psoriasis data for envudeucitinib
Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.
Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.